Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the ‘POPulation differences in VACcine responses’ (POPVAC) programme
Introduction Several licensed and investigational vaccines have lower efficacy, and induce impaired immune responses, in low-income versus high-income countries and in rural, versus urban, settings. Understanding these population differences is essential to optimising vaccine effectiveness in the tr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-02-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/11/2/e040426.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849221307527331840 |
|---|---|
| author | Pontiano Kaleebu Emily Webb Moses Muwanga Gyaviira Nkurunungi Ludoviko Zirimenya Agnes Natukunda Jacent Nassuuna Gloria Oduru Caroline Ninsiima Christopher Zziwa Florence Akello Robert Kizindo Mirriam Akello Anne Wajja Henry Luzze Stephen Cose Alison M Elliott Alison Elliott Rebecca Amongin Beatrice Nassanga Irene Nambuya Prossy Kabuubi Emmanuel Niwagaba Grace Kabami Helen Akurut Alex Mutebe Milly Namutebi Caroline Onen Esther Nakazibwe Josephine Tumusiime Susan Amongi Moses Sewankambo Denis Nsubuga Samuel Kiwanuka Fred Kiwudhu David Abiriga Moses Kizza Samsi Nansukusa Hermelijn Smits Maria Yazdanbakhsh Govert van Dam Paul Corstjens Sarah Staedke James Kaweesa Edridah Tukahebwa Elly Tumushabe Prossy N Kabuubi Joel Serubanja |
| author_facet | Pontiano Kaleebu Emily Webb Moses Muwanga Gyaviira Nkurunungi Ludoviko Zirimenya Agnes Natukunda Jacent Nassuuna Gloria Oduru Caroline Ninsiima Christopher Zziwa Florence Akello Robert Kizindo Mirriam Akello Anne Wajja Henry Luzze Stephen Cose Alison M Elliott Alison Elliott Rebecca Amongin Beatrice Nassanga Irene Nambuya Prossy Kabuubi Emmanuel Niwagaba Grace Kabami Helen Akurut Alex Mutebe Milly Namutebi Caroline Onen Esther Nakazibwe Josephine Tumusiime Susan Amongi Moses Sewankambo Denis Nsubuga Samuel Kiwanuka Fred Kiwudhu David Abiriga Moses Kizza Samsi Nansukusa Hermelijn Smits Maria Yazdanbakhsh Govert van Dam Paul Corstjens Sarah Staedke James Kaweesa Edridah Tukahebwa Elly Tumushabe Prossy N Kabuubi Joel Serubanja |
| collection | DOAJ |
| description | Introduction Several licensed and investigational vaccines have lower efficacy, and induce impaired immune responses, in low-income versus high-income countries and in rural, versus urban, settings. Understanding these population differences is essential to optimising vaccine effectiveness in the tropics. We suggest that repeated exposure to and immunomodulation by chronic helminth infections partly explains population differences in vaccine response.Methods and analysis We have designed an individually randomised, parallel group trial of intensive versus standard praziquantel (PZQ) intervention against schistosomiasis, to determine effects on vaccine response outcomes among school-going adolescents (9–17 years) from rural Schistosoma mansoni-endemic Ugandan islands. Vaccines to be studied comprise BCG on day ‘zero’; yellow fever, oral typhoid and human papilloma virus (HPV) vaccines at week 4; and HPV and tetanus/diphtheria booster vaccine at week 28. The intensive arm will receive PZQ doses three times, each 2 weeks apart, before BCG immunisation, followed by a dose at week 8 and quarterly thereafter. The standard arm will receive PZQ at week 8 and 52. We expect to enrol 480 participants, with 80% infected with S. mansoni at the outset.Primary outcomes are BCG-specific interferon-γ ELISpot responses 8 weeks after BCG immunisation and for other vaccines, antibody responses to key vaccine antigens at 4 weeks after immunisation. Secondary analyses will determine the effects of intensive anthelminthic treatment on correlates of protective immunity, on waning of vaccine response, on priming versus boosting immunisations and on S. mansoni infection status and intensity. Exploratory immunology assays using archived samples will enable assessment of mechanistic links between helminths and vaccine responses.Ethics and dissemination Ethics approval has been obtained from relevant ethics committes of Uganda and UK. Results will be shared with Uganda Ministry of Health, relevant district councils, community leaders and study participants. Further dissemination will be done through conference proceedings and publications.Trial registration number ISRCTN60517191. |
| format | Article |
| id | doaj-art-0046f191741b4bd285f9b6dcba978b90 |
| institution | Kabale University |
| issn | 2044-6055 |
| language | English |
| publishDate | 2021-02-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-0046f191741b4bd285f9b6dcba978b902024-11-17T06:50:08ZengBMJ Publishing GroupBMJ Open2044-60552021-02-0111210.1136/bmjopen-2020-040426Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the ‘POPulation differences in VACcine responses’ (POPVAC) programme 0Pontiano Kaleebu1Emily Webb2Moses MuwangaGyaviira Nkurunungi3Ludoviko Zirimenya4Agnes Natukunda5Jacent Nassuuna6Gloria Oduru7Caroline Ninsiima8Christopher Zziwa9Florence Akello10Robert Kizindo11Mirriam Akello12Anne Wajja13Henry Luzze14Stephen Cose15Alison M Elliott16Alison Elliott17Rebecca Amongin18Beatrice NassangaIrene NambuyaProssy KabuubiEmmanuel Niwagaba19Grace Kabami20Helen AkurutAlex Mutebe21Milly Namutebi22Caroline Onen23Esther Nakazibwe24Josephine TumusiimeSusan Amongi25Moses Sewankambo26Denis Nsubuga27Samuel Kiwanuka28Fred Kiwudhu29David AbirigaMoses KizzaSamsi NansukusaHermelijn SmitsMaria YazdanbakhshGovert van DamPaul CorstjensSarah StaedkeJames Kaweesa30Edridah TukahebwaElly TumushabeProssy N Kabuubi31Joel Serubanja4Association of British Neurologists1 MRC/UVRI and LSHTM Uganda Research Unit, Kampala, UgandaMRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UKImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, UgandaUganda National Expanded Program on Immunisation, Ministry of Health, Kampala, UgandaImmunomodulation and Vaccines Programme, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaClinical Research Department, London School of Hygiene & Tropical Medicine, London, UKImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaVector Control Division, Republic of Uganda Ministry of Health, Kampala, UgandaImmunomodulation and Vaccines Programme, MRC/UVRI and LSHTM Uganda Research Unit, Entebbe, UgandaIntroduction Several licensed and investigational vaccines have lower efficacy, and induce impaired immune responses, in low-income versus high-income countries and in rural, versus urban, settings. Understanding these population differences is essential to optimising vaccine effectiveness in the tropics. We suggest that repeated exposure to and immunomodulation by chronic helminth infections partly explains population differences in vaccine response.Methods and analysis We have designed an individually randomised, parallel group trial of intensive versus standard praziquantel (PZQ) intervention against schistosomiasis, to determine effects on vaccine response outcomes among school-going adolescents (9–17 years) from rural Schistosoma mansoni-endemic Ugandan islands. Vaccines to be studied comprise BCG on day ‘zero’; yellow fever, oral typhoid and human papilloma virus (HPV) vaccines at week 4; and HPV and tetanus/diphtheria booster vaccine at week 28. The intensive arm will receive PZQ doses three times, each 2 weeks apart, before BCG immunisation, followed by a dose at week 8 and quarterly thereafter. The standard arm will receive PZQ at week 8 and 52. We expect to enrol 480 participants, with 80% infected with S. mansoni at the outset.Primary outcomes are BCG-specific interferon-γ ELISpot responses 8 weeks after BCG immunisation and for other vaccines, antibody responses to key vaccine antigens at 4 weeks after immunisation. Secondary analyses will determine the effects of intensive anthelminthic treatment on correlates of protective immunity, on waning of vaccine response, on priming versus boosting immunisations and on S. mansoni infection status and intensity. Exploratory immunology assays using archived samples will enable assessment of mechanistic links between helminths and vaccine responses.Ethics and dissemination Ethics approval has been obtained from relevant ethics committes of Uganda and UK. Results will be shared with Uganda Ministry of Health, relevant district councils, community leaders and study participants. Further dissemination will be done through conference proceedings and publications.Trial registration number ISRCTN60517191.https://bmjopen.bmj.com/content/11/2/e040426.full |
| spellingShingle | Pontiano Kaleebu Emily Webb Moses Muwanga Gyaviira Nkurunungi Ludoviko Zirimenya Agnes Natukunda Jacent Nassuuna Gloria Oduru Caroline Ninsiima Christopher Zziwa Florence Akello Robert Kizindo Mirriam Akello Anne Wajja Henry Luzze Stephen Cose Alison M Elliott Alison Elliott Rebecca Amongin Beatrice Nassanga Irene Nambuya Prossy Kabuubi Emmanuel Niwagaba Grace Kabami Helen Akurut Alex Mutebe Milly Namutebi Caroline Onen Esther Nakazibwe Josephine Tumusiime Susan Amongi Moses Sewankambo Denis Nsubuga Samuel Kiwanuka Fred Kiwudhu David Abiriga Moses Kizza Samsi Nansukusa Hermelijn Smits Maria Yazdanbakhsh Govert van Dam Paul Corstjens Sarah Staedke James Kaweesa Edridah Tukahebwa Elly Tumushabe Prossy N Kabuubi Joel Serubanja Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the ‘POPulation differences in VACcine responses’ (POPVAC) programme BMJ Open |
| title | Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the ‘POPulation differences in VACcine responses’ (POPVAC) programme |
| title_full | Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the ‘POPulation differences in VACcine responses’ (POPVAC) programme |
| title_fullStr | Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the ‘POPulation differences in VACcine responses’ (POPVAC) programme |
| title_full_unstemmed | Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the ‘POPulation differences in VACcine responses’ (POPVAC) programme |
| title_short | Effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural Ugandan island adolescents: randomised controlled trial protocol A for the ‘POPulation differences in VACcine responses’ (POPVAC) programme |
| title_sort | effect of intensive treatment for schistosomiasis on immune responses to vaccines among rural ugandan island adolescents randomised controlled trial protocol a for the population differences in vaccine responses popvac programme |
| url | https://bmjopen.bmj.com/content/11/2/e040426.full |
| work_keys_str_mv | AT effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT pontianokaleebu effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT emilywebb effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT mosesmuwanga effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT gyaviirankurunungi effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT ludovikozirimenya effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT agnesnatukunda effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT jacentnassuuna effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT gloriaoduru effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT carolineninsiima effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT christopherzziwa effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT florenceakello effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT robertkizindo effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT mirriamakello effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT annewajja effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT henryluzze effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT stephencose effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT alisonmelliott effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT alisonelliott effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT rebeccaamongin effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT beatricenassanga effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT irenenambuya effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT prossykabuubi effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT emmanuelniwagaba effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT gracekabami effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT helenakurut effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT alexmutebe effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT millynamutebi effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT carolineonen effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT esthernakazibwe effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT josephinetumusiime effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT susanamongi effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT mosessewankambo effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT denisnsubuga effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT samuelkiwanuka effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT fredkiwudhu effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT davidabiriga effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT moseskizza effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT samsinansukusa effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT hermelijnsmits effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT mariayazdanbakhsh effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT govertvandam effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT paulcorstjens effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT sarahstaedke effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT jameskaweesa effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT edridahtukahebwa effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT ellytumushabe effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT prossynkabuubi effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme AT joelserubanja effectofintensivetreatmentforschistosomiasisonimmuneresponsestovaccinesamongruralugandanislandadolescentsrandomisedcontrolledtrialprotocolaforthepopulationdifferencesinvaccineresponsespopvacprogramme |